Encompass Health Files 8-K

TL;DR

Encompass Health filed an 8-K on 9/12/25, standard corporate update.

AI Summary

Encompass Health Corporation filed an 8-K on September 12, 2025, to report information under Regulation FD. The filing details the company's principal executive offices located at 9001 Liberty Parkway, Birmingham, Alabama, 35242, and its primary business operations within the hospital services sector.

Why It Matters

This filing serves as an official notification to the SEC and the public regarding Encompass Health's corporate information and regulatory compliance.

Risk Assessment

Risk Level: low — This is a routine corporate filing with no new material financial or operational information disclosed.

Key Players & Entities

• Encompass Health Corporation (company) — Registrant
• 9001 Liberty Parkway, Birmingham, Alabama, 35242 (location) — Principal Executive Offices
• September 12, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share EHC New York Stock Exchange
• $5,880 million — 2025 ranges: Net operating revenue of $5,880 million to $5,980 million; Adjusted EBITDA of
• $5,980 million — operating revenue of $5,880 million to $5,980 million; Adjusted EBITDA of $1,220 million to
• $1,220 million — to $5,980 million; Adjusted EBITDA of $1,220 million to $1,250 million; and Adjusted earnin
• $1,250 million — ; Adjusted EBITDA of $1,220 million to $1,250 million; and Adjusted earnings per share from
• $5.12 — ons attributable to Encompass Health of $5.12 to $5.34. The information contained he
• $5.34 — butable to Encompass Health of $5.12 to $5.34. The information contained herein is b
• $125 million — debt discounts and fees - approximately $125 million Amortization of debt-related items - a
• $10 million — n of debt-related items - approximately $10 million Forward-Looking Statements Statement

Filing Documents

• ehc-20250912.htm (8-K) — 32KB
• 0000785161-25-000070.txt ( ) — 147KB
• ehc-20250912.xsd (EX-101.SCH) — 2KB
• ehc-20250912_lab.xml (EX-101.LAB) — 21KB
• ehc-20250912_pre.xml (EX-101.PRE) — 12KB
• ehc-20250912_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

ITEM 7.01. Regulation FD Disclosure. Members of Encompass Health Corporation's (the "Company" or "Encompass Health") senior management team are scheduled to meet with investors and analysts at various meetings on September 12, 2025, October 1, 2025, and October 6, 2025. The Company reiterates as of the date hereof its guidance previously reported in the Current Report on Form 8-K, dated August 4, 2025, and during the Company's earnings conference call held on August 5, 2025. Accordingly, the Company continues to expect the following full-year 2025 ranges: Net operating revenue of $5,880 million to $5,980 million; Adjusted EBITDA of $1,220 million to $1,250 million; and Adjusted earnings per share from continuing operations attributable to Encompass Health of $5.12 to $5.34. The information contained herein is being furnished pursuant to Item 7.01 of Form 8-K, "Regulation FD Disclosure." This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained herein. Note Regarding Presentation of Non-GAAP Financial Measures Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to

Forward-Looking Statements

Forward-Looking Statements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. ENCOMPASS HEALTH CORPORATION By: / S / D OUGLAS E. C OLTHARP Name: Douglas E. Coltharp Title: Executive Vice President and Chief Financial Officer Dated: September 12, 2025

View Full Filing

View this 8-K filing on SEC EDGAR